Stem Cells Spin SA
0.47
PLN
0.00
(0.00%)
ISIN
PLSTCLS00013
Return %
Stock
S&P 500
1Y
15.76
14.20
3Y
30.56
81.12
5Y
-38.96
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Wroclaw Poland
- IPO Date
- Oct 25, 2011
- Website
- stemcellsspin.com.pl
- Similar Companies
- Business
- Stem Cells Spin S.A. is a Poland-based biotechnology company engaged in the research, development, and commercialization of regenerative medicine solutions, bioactive preparations, and therapeutic applications based on proprietary stem cell technologies. Founded in 2009 as an academic spin-off from Wroclaw Medical University and headquartered in Wroclaw, Poland, the company operates within the biotechnology and life sciences sector, serving consumers, dermatological practitioners, veterinary clinics, and clinical research institutions primarily across Poland and the European Union. Stem Cells Spin leverages an internationally patented biological platform centered on MIC-1 stem cells, an embryonic-like stem cell line derived from the regenerating antlerogenic tissue of deer. The company develops, manufactures, and supplies products across three core segments: dermocosmetics, veterinary medicine, and medical devices. Its commercial portfolio and product pipeline include anti-aging and regenerative cosmetic skincare lines marketed under the Revitacell and Velvetyna brand names; specialized veterinary regenerative preparations and topical dermatological solutions distributed under the NHAC Biocervin MIC-1 and PRS MIC-1 brands; contract production and supply of active cellular extracts and conditioned media rich in regenerative proteins and growth factors; and research-stage Advanced Therapy Medicinal Products (ATMPs) and medical devices targeting tissue regeneration in ophthalmology, neurosurgery, and pulmonology. In recent developments, the company has undertaken strategic capital increases on the Warsaw Stock Exchange NewConnect market (Ticker: GPW:SCS) to fund preclinical and clinical development phases, implemented corporate governance adjustments through management board appointments, and oriented its primary business focus toward securing regulatory pathways and partnership agreements for human medical device applications and international commercial distribution.